Radioprotectin-1 is a potent and specific nonlipid agonist of lysophosphatidic acid receptor 2 (LPA 2 ) , with an EC 50 value of 25 nM for murine LPA 2 subtype.
Storage Temp
Store at -20°C
Shipped In
Ice chest + Ice pads
Product Description
Radioprotectin-1 is a potent and specific nonlipid agonist of lysophosphatidic acid receptor 2 (LPA 2 ) , with an EC 50 value of 25 nM for murine LPA 2 subtype
In Vitro
Radioprotectin-1 is a potent agonist of LPA 2 with an EC 50 of 5 pM and functions as a full agonist at the human ortholog of LPA 2. Radioprotectin-1 (0-3 μM; 15 minutes) effectively reduces apoptosis induced by γ-irradiation and the radiomimetic drug Adriamycin in cells that expressed LPA 2 either endogenously or after transfection. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: MEF cells , IEC-6 cells Concentration: 0 μM, 0.1 μM, 0.3 μM, 1.0 μM,3 μM Incubation Time: 15 minutes Result: Protected cells from apoptosis by γ-irradiation- and the radiomimetic chemotherapeutic\nAdiamycin.
In Vivo
Radioprotectin-1 is a high-potency specific agonist of the murine LPA 2 GPCR . Radioprotectin-1 (0.1 mg/kg, 0.3 mg/kg; s.c.; every 12 hours; for 3 days) decreases the mortality of C57BL/6 mice in models of the hematopoietic acute radiation syndromes (HE-ARS) and gastrointestinal acute radiation syndromes (GI-ARS) . Radioprotectin-1 exerts its radioprotective and radiomitigative action through specific activation of the upregulated LPA 2 GPCR in Lgr5 + stem cells . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 8-10 weeks old C57BL/6 female mice bearing total body irradiation (TBI) Dosage: 0.1 mg/kg, 0.3 mg/kg Administration: Subcutaneous injection; every 12 hours; for 3 days Result: Decreased mortality of C57BL/6 mice in models of the HE-ARS and the GI-ARS.
